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Abstract Protein disulfide isomerase (PDI) exhibits both an
oxido-reductase and an isomerase activity on proteins containing
cysteine residues. These activities arise from two active sites,
both of which contain pairs of redox active cysteines. We have
developed two simple in vivo assays for these activities of PDI,
based on the demonstration that PDI can complement both a
dsbA mutation and a dsbC mutation when expressed to the
periplasm of Escherichia coli. We constructed a variety of
mutants in and around the active sites of PDI and analysed them
using these complementation assays. Our analysis showed that
the active site amino acid residues have a major role in
determining the activities exhibited by PDI, particularly the N-
terminal cysteine of the N-terminal active site. The roles of the
histidine residue at position 38 and the glutamic acid residue at
position 30 were also studied using these assays. The results show
that these two in vivo assays should be useful for rapid screening
of mutants in PDI prior to purification and detailed biochemical
analysis.
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1. Introduction
Protein disul¢de isomerase (PDI), a resident of the lumen of
the endoplasmic reticulum of eukaryotic cells, catalyses the
isomerisation and net formation of disul¢de bonds in folding
proteins (for reviews see [1^5]). The initial characterisation of
PDI involved its ability to catalyse the oxidative refolding of
reduced RNase in vitro [6]. Further demonstrations of PDI
activity have included the restoration of defective co-transla-
tional disul¢de bond formation in PDI-de¢cient microsomes
of the endoplasmic reticulum [7], the complementation of a
phenotype associated with defective disul¢de bond formation
in vivo in Escherichia coli [8,9], in vivo analysis in Saccharo-
myces cerevisiae [10], and the assisted folding of various model
substrate proteins in vitro [11^17]. PDI has also been demon-
strated to exhibit activities separate from dithiol :disul¢de in-
terchange. It has been identi¢ed as the L-subunits of both
human prolyl 4-hydroxylase [18] and the microsomal triacyl-
glycerol transfer protein [19] where the putative role of PDI is
to maintain the K-subunits in an active conformation [20^22].
PDI also has chaperone activity, demonstrated by its ability to
help the folding of non-disul¢de-bonded substrate proteins
[23,24]. This requires non-covalent binding of PDI to protein
substrates, which has been experimentally demonstrated [25^
30]. The ability of PDI to bind peptide and its dithiol:disul¢de
interchange activities appeared linked in that the full multi-
domain structure of the PDI molecule is required for the
e⁄cient catalysis of most dithiol :disul¢de reactions by PDI
[31].
PDI has two conserved thioredoxin (Trx)-like active sites
with the ubiquitous redox active CXXC motifs which are
typical of this family of proteins. Early work on PDI demon-
strated its cysteine residues to be essential for its enzymatic
activity. Biochemical modi¢cation of the active site cysteine
residues of PDI caused irreversible inactivation of the protein
[32]. Subsequently, PDI molecules were produced with various
active site cysteine to serine or alanine substitutions, some of
which had a major in£uence on the dithiol :disul¢de inter-
change activities of PDI in vivo and in vitro [10,33^35]. De-
tailed studies of PDI using site-directed mutagenesis have
been hampered by the lack of a three-dimensional structure
for the protein and the relatively complex in vitro assays.
There is thus a need for a quick assay for rapid screening
of mutant proteins in vivo.
The periplasm is the site of isomerisation and net formation
of disul¢de bonds in E. coli. The major catalyst of net for-
mation of disul¢de bonds in E. coli is DsbA [36^38]. Isomer-
isation is catalysed predominantly by the DsbC protein, the
activity of which has been demonstrated both in vitro and in
vivo [39^42]. We have previously demonstrated that human
PDI expressed to the periplasm can complement a dsbA mu-
tant in E. coli, using alkaline phosphatase, which requires
oxidase but not isomerase activity for its e⁄cient folding, as
an in vivo substrate [8]. In this study, we show that human
PDI can complement a dsbC-dependent phenotype on a sub-
strate (mouse urokinase, mUK) that requires the action of an
isomerase to fold e⁄ciently. Thus, we can distinguish and
quantify the oxidase and isomerase activities of PDI in two
simple in vivo assays. We used these assays to analyse the
e¡ects of a series of site-directed mutants in and around the
active sites of PDI. The various forms of PDI produced dif-
fered greatly in their ability to complement dsbA and dsbC
phenotypes in vivo in E. coli. This enabled us to screen for
amino acid residues critical to the ability of PDI to catalyse
the isomerisation and net formation of disul¢de bonds in
folding protein.
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2. Materials and methods
2.1. Materials
Unless otherwise stated all growth media were obtained from BBL,
and all chemicals from BDH or Fisher Scienti¢c. All restriction en-
zymes and modifying enzymes were obtained from New England Bio-
labs. Mutagenic primers and sequencing primers were obtained from
Alta Biosciences (University of Birmingham). VCMS13 Helper phage
was obtained from Stratagene, kanamycin and chloramphenicol from
Sigma, carbenicillin from Duchefa Biochemie BV (Netherlands), plas-
minogen from Calbiochem, rabbit polyclonal anti-bovine PDI anti-
body from BioQuote, secondary HRP-conjugated polyclonal anti-rab-
bit antibody from Sigma, Hybond C from Amersham and fat-free
powdered milk from Marvel.
2.2. Bacterial strains and plasmids
Plasmids and bacterial strains used in this study are listed in Table
1.
2.3. General DNA manipulations, immunoblotting and detection
Standard methods were used [47,48].
2.4. Growth conditions
Cultures grown in Luria broth supplemented with antibiotics were
shaken (200 rpm) at 37‡C. Expression of PDI from pDPH5 [8] was
from the uninduced trp promoter. Expression of mUK from pJRS7
was induced by inclusion of arabinose at a concentration of 0.2%
(w/v).
2.5. Plasmid and strain construction
A BamHI/HindIII fragment from pDPH5 containing the PDI gene
was ligated into the pMac5.8 vectors producing plasmids pJRS1 and
pJRS2 respectively. Oligonucleotide-directed mutagenesis of PDI was
carried out in these plasmids by the gapped-duplex method [46]; the
plasmids were designated pJRS2-x where x was the number of the
particular mutation. Oligonucleotides used are shown in Table 2.
BamHI/HindIII fragments from pJRS2-x plasmids containing muta-
genised forms of the PDI gene were ligated into pDPH5, producing
the pJRS3-x series of plasmids. An Eco47III/BglI fragment of
pBAD33mUK was blunt ended by treatment with T4 DNA polymer-
ase and then ligated into plasmid pDPH5 which had previously been
digested with BamHI and the ends ¢lled in by treatment with Klenow.
The resulting plasmid (pJRS7) expresses PDI from the trp promoter
and mUK from the pBAD promoter. PvuI/XbaI fragments of pJRS3-
x plasmids containing mutagenised forms of PDI were ligated into
pJRS7 to produce the pJRS7-x series of plasmids. As a control, a
PvuI/HpaI fragment of pCT54 was ligated into pJRS7 producing
pJRS8 which expresses mUK but not PDI. Plasmids in the pJRS2-
x, pJRS3-x and pJRS7-x series were demonstrated to contain the
desired mutational changes by restriction digestion and additionally
by sequencing in the pJRS3-x plasmids (data not shown).
TG1 strains carrying mutations of the dsbA and dsbC genes were
constructed using P1 transduction [49] from RI90 and RI179 respec-
tively.
2.6. Assays of PDI dithiol:disul¢de interchange activities
The alkaline phosphatase and urokinase (zymogram) assays were
performed as described earlier [8,42]. Zymograms were approximately
quanti¢ed by measuring the zones of clearing by optical densitometry
using an IS-1000 Digital Imaging System (Alpha Innotech Corp.)
using the software provided (AlphaImager 2000) and displaying
them graphically. A calibration curve was constructed by making
several dilutions of bacterial periplasmic extract from JRS3 containing
pJRS7, and the activity exhibited by the PDI mutants when comple-
menting the dsbC phenotype was estimated by comparison with this
curve.
3. Results and discussion
3.1. PDI can complement a dsbC mutation in E. coli
We ¢rst studied the ability of periplasmic PDI to act as an
isomerase in E. coli, using as a substrate the protein mUK
(which contains 12 disul¢de bonds) [42]. This protein was used
by Rietsch et al. [42] to assay for the in vivo activity of the
DsbC protein. When mUK is expressed to the E. coli peri-
plasm, it requires the activity of the DsbC protein in order to
reach its active state, which can then be detected on a zymo-
gram using plasminogen as a substrate. The 12 disul¢de bonds
of the mUK protein must be correctly formed to produce
functional protein [42]. We expressed mUK to the periplasm
using plasmid pJRS7 which contains the mUK gene under the
control of the arabinose-inducible pBAD promoter and PDI
under the control of the trp promoter. As a control the plas-
mid pJRS8 was used which expresses mUK but not PDI.
These plasmids were transformed into the dsbC strain JRS3
and production of active mUK was detected using zymograms
as described in Section 2. The results are shown in Fig. 1.
As can be seen, expression of PDI restored mUK activity in
the dsbC strain whereas in the absence of PDI, no mUK
activity was detectable. We conclude from this that the PDI
is acting as an isomerase in the E. coli periplasm.
3.2. Analysis of mutations in the redox active cysteines of PDI
Initially, we constructed single Cys to Ser changes in each
of the four redox active cysteines of PDI. We then determined
the oxidase activity of PDI by measurement of alkaline phos-
phatase activity in a dsbA background, and the isomerase
Table 1
Bacterial strains and plasmids used in this study
Strain/plasmid Genotype/important features Source or reference
RI89 MC1000 phoR vara714 [42]
RI90 RI89 dsbA: :kan1 [42]
RI179 RI89 vdsbC: :cam [42]
WK6 v(lac-proAB) galE strA/FP traD36 lacIq lacZDM15, proAB [43]
WK6mutS WK6 mutS : :Tn10 [43]
TG1 supE hsdD5 thi v(lac-proAB)/FP traD36 proAB lacIq lacZvM15 [44]
JRS1 TG1 dsbA: :kan1 This study
JRS3 TG1 vdsbC: :cam This study
pCT54 Expression plasmid, trp promoter, ColE1 origin, AmpR [45]
pDPH5 pCT54 expressing PDI from trp promoter [8]
pMa5.8 f1 origin, colE1 origin, AmpR, CmS [46]
pMc5.8 f1 origin, colE1 origin, AmpS, CmR [46]
pJRS3-x pDPH5 with mutagenised PDI This study
pBAD33mUK mUK expression plasmid, pBAD promoter, pACYC184 origin, CmR D. Belin
pJRS7-x Plasmids expressing wild type or mutagenised PDIs and mUK from the trp and pBAD
promoters respectively, colE1 origin, AmpR
This study
pJRS8 Control plasmid expressing mUK from the pBAD promoter, colE1 origin, AmpR This study
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activity by measurement of mUK activity in a dsbC back-
ground. The e¡ects on oxidase and isomerase activity in our
experiments were dramatically di¡erent (Table 3). None of the
mutations had any signi¢cant e¡ect on the in vivo oxidase
activity of PDI. However, mutation of either of the two cys-
teines in active site one led to a complete loss of isomerase
activity in vivo. Mutation of either of the two cysteines in
active site two led to a severe reduction in isomerase activity,
particularly for mutation of the ¢rst cysteine (Table 3, rows 2^
5).
These results demonstrate two things. First, the require-
ments for redox active cysteines for isomerase activity are
clearly more stringent than for oxidase activity. Second,
with regard to isomerase activity there is evidence for some
non-equivalence between the two sites, with site one being
more important than site two. This has also been demon-
strated by in vitro assays [50], although other investigations
suggested that both active sites contribute equally to the iso-
merase activity of PDI and thus inactivation of either site led
to a loss of 50% of the activity [33]. We considered the pos-
sibility that a di¡erence in activity might be seen if assays were
performed on cultures before they reached saturation, but
experiments on cultures at di¡erent times in their growth
failed to reveal any such di¡erence (data not shown). The
di¡erence between di¡erent studies may arise from the use
of di¡erent substrates or from the conditions under which
the assays were carried out.
We next looked at the e¡ects of mutating both of the active
site cysteines in one or the other of the two active sites (Table
3, rows 6 and 7). Oxidase activity was una¡ected by this; the
PDI with either site one or site two inactivated by mutation of
both cysteine residues to serine still gave 100% alkaline phos-
phatase activity in a dsbA background. Isomerase activity in
contrast was completely lost if the ¢rst active site was mutated
and largely though not completely lost if the second site was
inactivated, further supporting the suggestion that the two
sites are non-equivalent with regard to isomerase activity [50].
The fact that the oxidase activity of PDI was una¡ected in
our assays by inactivation of either one of the two active sites
enabled us to look at the contribution of the di¡erent cysteine
residues of each site to the activity, without any background
activity from the other site (Table 3, rows 8^11). Mutation of
the ¢rst cysteine to a serine in either site one or site two, with
the other site inactivated, led to complete loss of oxidase
activity. Mutation of the second cysteine to serine in site
one (with no active site two) led to an approximately 50%
loss of activity, whereas mutation of the second cysteine in
site two (with no active site one) led to an approximately 70%
loss of activity. These results were again consistent with a
degree of non-equivalence between the two sites and also
demonstrated that the ¢rst cysteine is the crucial one in the
oxidase activity of PDI. We thus predicted that a double
mutant where both the ¢rst cysteines in active sites one and
two were changed to serine would be inactive, for both oxi-
dase and isomerase activity, whereas a double mutant with
both the second cysteines mutated would retain some oxidase
activity but no isomerase activity. This prediction was con-
¢rmed (Table 3, rows 12 and 13). A mutant with all four
cysteine residues converted to serines has no oxidase activity
above background, as expected (Table 3, rows 14 and 15).
These results agree in part with previous studies [33,34],
which identi¢ed the ¢rst cysteine of both active sites as essen-
tial for the oxidase and isomerase activities of PDI. However,
our data identify the second cysteine of both active sites as
being essential for isomerase activity only. This is discussed
later.
3.3. Analysis of other active site mutations in PDI
The E. coli proteins DsbA, DsbC, and Trx, and PDI, all
contain the same active site cysteine residues but show dra-
matically di¡erent in vivo and in vitro activities. DsbA is
active primarily as an dithiol oxidase, DsbC as an isomerase,
PDI as both, and Trx as a reductase. Alignments of the
known polypeptide sequences of PDI, DsbA, DsbC and Trx
shows the di¡erences in and around the active site for each
protein (see Fig. 2). The requirements for some of these amino
acids in the bacterial proteins have already been analysed [51^
58]. We therefore made changes in the ¢rst PDI active site
Table 2
Oligonucleotides used for construction of mutations in PDI
Oligonucleotidea Restriction enzymeb Amino acid change
5P-GGGGCATAGAAGACCACCAGCAGG-3P BbsI E30V
5P-GCAGTGACCGCTCCATGGGGC-3P BsrBI C36S/C380S
5P-GGCCAGAGCCTTGGAGTGGCC-3P BstXI C39S
5P-GGGAGCCAACTGTTTGGAGTGACC-3P BstXI C383S
5P-GCCTTGCAGTGCGGGCACCAAGGG-3P BanI G37P
5P-GCCTTGCACGGACCACACCAAGGG-3P AvaII H38P
5P-GCCTTGCACTAGCCACACCAAGGG-3P BfaI H38Y
5P-GCCTTGCAGAGGCCACACCAAGGG-3P EcoNI H38L
5P-GCCAGAGCCTTACAGCGGCCGCACCAAGGG-3P EagI H38R
aChanges in the oligonucleotides from the wild type PDI DNA sequence are underlined.
bThe restriction endonuclease used to initially check the successful mutagenesis of the PDI gene.
Fig. 1. Zymogram demonstrating the ability of PDI to complement
the e¡ect of dsbC mutation on urokinase activity. Lysates of cul-
tures induced with 0.2% (w/v) arabinose and grown to an OD600 of
approximately 1.0 were separated on non-reducing SDS-PAGE gels.
Urokinase activity was shown by activation of plasminogen on plas-
minogen/casein agar. Zymograms of lysates are from strains TG1
containing pJRS8 and pJRS7 (lanes 1 and 2), JRS3 (TG1 vdsbC)
containing pJRS8 and pJRS7 (lanes 3 and 4) and JRS3 containing
pJRS7-x plasmids expressing PDI with the amino acid changes
C383S, C380S, C36S, H38Y and H38P (lanes 5, 6, 7, 8 and 9 re-
spectively). A typical zymogram of three independent experiments is
shown.
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that made it more closely resemble the active sites from the
di¡erent bacterial proteins, and analysed their e¡ect on both
the oxidase and isomerase activities of PDI.
Mutation of the glycine residue at position 37 to a proline
(found in the corresponding position in DsbA, which acts
predominantly as an oxidase) did not reduce the oxidase ac-
tivity of PDI but completely inactivated the isomerase activity
irrespective of the presence or absence of a functional site two
(Table 4, rows 3 and 4). Mutation of the histidine at position
38 to a proline as found in Trx, completely abolished the
oxidase activity of PDI but intriguingly left a small residual
isomerase activity (Table 4, rows 5 and 6). Mutation of the
same histidine to a tyrosine (found in DsbC) led to a signi¢-
cant loss of oxidase activity, but although the isomerase ac-
tivity was also reduced when combined with an unchanged
site two, it was greater than that seen with a wild type site
one and an inactivated site two (Table 4, rows 7 and 8). Thus
in all cases, the changes in site one had the same e¡ect on the
particular activity being assayed irrespective of the nature of
site two. The reason for this unexpected result is not clear, but
it was highly reproducible.
The changes introduced above to mimic the active site se-
quences of other redox proteins pointed to the histidine resi-
due at position 38 of PDI as having a key role in the dithiol :
disul¢de interchange activities of PDI. We investigated the
e¡ects of changing this residue to a more basic residue (argi-
nine) or a neutral one (leucine). Both of these changes caused
a complete loss of isomerase activity, irrespective of the pres-
ence or absence of an active site two (Table 4, rows 9^12).
These mutations had no e¡ect on the oxidase phenotype when
an active site two was present, but in the absence of an active
site two, mutation to leucine caused a very signi¢cant loss of
oxidase activity.
Finally we looked at the possible role of the glutamate
residue at position 30. This residue was chosen for study be-
cause the equivalent residue in Trx, aspartate 26, has been
proposed to play an important role in the second stage of
disul¢de reduction as catalysed by Trx, acting as a proton
acceptor to facilitate the ionisation of the second active site
cysteine to the reactive thiolate form, which has a key cata-
lytic role in the isomerase activity of PDI [54,55,59,60]. Our
earlier results had already demonstrated that the second cys-
teine is not required for oxidase activity in our assay, thus
mutation of glutamate 30 to a neutral residue such as valine
was predicted to have little or no e¡ect on the oxidase activity
but to reduce or destroy the isomerase activity of PDI. The
results obtained con¢rmed that this was indeed the case (Ta-
ble 4, rows 13 and 14).
In this study we have demonstrated the ability of PDI to
catalyse the isomerisation and net formation of disul¢de
bonds by complementation of dsbA and dsbC mutations in
E. coli. This enabled us to quantify the importance of the
active site residues to the dithiol :disul¢de interchange activ-
ities of PDI. The ¢rst cysteine of both PDI active sites is
essential for the ability of PDI to catalyse the isomerisation
and net formation of disul¢de bonds. We showed that the
histidine residue at position 38 is critical for PDI function
and that the glutamate residue at position 30 is required by
Table 3
Oxidase and isomerase activities of PDI and PDI mutants with CysCSer replacements in the active sites, determined in vivo
Amino acids in PDI at active sites (mutagenised bases underlined) Alkaline phosphatase activitya Urokinase activityb
N-terminal active site C-terminal active site
1 CGHC CGHC 100 100
2 SGHC CGHC 97 0
3 CGHS CGHC 103 0
4 CGHC SGHC 96 6.3
5 CGHC CGHS 87 12.5
6 SGHS CGHC 100 0
7 CGHC SGHS 94 3.1
8 SGHC SGHS 12 0
9 SGHS SGHC 14 0
10 CGHS SGHS 56 0
11 SGHS CGHS 29 0
12 SGHC SGHC 12 0
13 CGHS CGHS 64 0
14 SGHS SGHS 10 0
15 no PDI no PDI 11 0
aResults are shown as percentage restoration of alkaline phosphatase activities compared to wild type PDI. The means of at least ¢ve inde-
pendent experiments are shown, standardised against the activity of wild type PDI in RI90.
bResults are shown as percentage restoration of urokinase activities compared to wild type PDI. The means of at least three independent ex-
periments were calculated, and standardised against the activity of wild type PDI in JRS3.
Fig. 2. Comparison of the active site sequences of various eukaryotic and prokaryotic oxidoreductase proteins [18,36,37,39,40,62,63]. The PDI
active site sequence is the N-terminal active site where the cysteine residues are at positions 36 and 39 of the PDI molecule. Multiple sequence
alignments were carried out using the ClustalW algorithm [61]. For PDI 17 polypeptide sequences from the SWISS-PROT database were ana-
lysed. For DsbA, DsbC and Trx 8, 4 and 46 sequences were analysed respectively. Conserved amino acid residues within a redox protein sub-
family are in bold.
FEBS 23155 21-1-00
S.J. Sta¡ord, P.A. Lund/FEBS Letters 466 (2000) 317^322320
PDI to facilitate the isomerisation of disul¢de bonds in fold-
ing protein.
In the absence of a three-dimensional structure for PDI,
mutagenic studies have to be based on homologies with other
proteins with related activities. The availability of these simple
in vivo assays for rapid screening of site-directed mutants
should considerably speed up the process of identifying mu-
tant forms of PDI for further study by puri¢cation and de-
tailed characterisation in vitro.
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